PATENTANWALTSKANZLEI DR. MEYER-DULHEUER & PARTNER

• Geschichte
• Leistungen
• Fachgebiete
• Anwälte
  • Dr. K.-H. Meyer-Dulheuer
  • Dr. Tim Meyer-Dulheuer, LL.M.
  • Dr. Holger Ludwig
  • Freia Andrea Breier, LL.M.
  • Dr. Matthias Heger
  • Junyi Früchtl
  • Dr. Sandra Loch
  • Angelika Fraas
  • Johanna Ganitta
  • Dr. Nina Schäper
• Mandanten
• Engagement
• Karriere

Dr. Holger Ludwig

Dr. Holger Ludwig hat während seiner Tätigkeiten an Instituten Greifswald bzw. Erlangen grundlegende mikrobiologische und biochemische Fragestellungen bearbeitet. Als Post-Doc bei der GSF in München sowie am Paul-Ehrlich-Institut in Langen arbeitete er virologisch sowie biochemisch an Projekten der innovativen Impfstoffentwicklung. Die dabei gewonnenen Forschungsergebnisse wurden in internationalen Fachzeitschriften publiziert. Herr Dr. Holger Ludwig hat in der Patentanwaltskanzlei Dr. Meyer-Dulheuer & Partner eine Ausbildung als Patentanwaltskandidat auf dem Gebiet des gewerblichen Rechtsschutzes absolviert. Seit 2010 ist er als Patentanwalt zugelassen und als solcher in der Patentanwaltskanzlei Dr. Meyer-Dulheuer & Partner tätig.

• 1994 bis 1999 Studium der Biologie an der Ernst-Moritz Arndt-Universität Greifswald
• 1999 bis 2002 Promotion an der Friedrich-Alexander-Universität Erlangen-Nürnberg am Lehrstuhl für Mikrobiologie
• 2003 Post-Doc am Institut für Molekulare Virologie der GSF - Forschungszentrum für Umwelt und Gesundheit in München
• 2004 bis 2006 Post-Doc am PAUL-EHRLICH-INSTITUT - Bundesamt für Sera und Impfstoffe in Langen in der Abteilung Virologie
• 2006 bis 2009 Patentanwaltskandidat in der Patentanwaltskanzlei Dr. Meyer-Dulheuer & Partner
• 2010 Zulassung als Patentanwalt
• seit 2010 Patentanwalt in der Patentanwaltskanzlei Dr. Meyer-Dulheuer & Partner

Sprachen: Deutsch, Englisch

1. Backes, S., K. M. Sperling, J. Zwilling, G. Gasteiger, H. Ludwig, E. Kremmer, A. Schwantes, C. Staib, and G. Sutter. 2010. Viral host-range factor C7 or K1 is essential for modified vaccinia virus Ankara late gene expression in human and murine cells, irrespective of their capacity to inhibit protein kinase R-mediated phosphorylation of eukaryotic translation initiation factor 2alpha. Journal of General Virology. 91:470-482.
   
   
2. Trilling, M., V. T. K. Le, A. Zimmermann, H. Ludwig, K. Pfeffer, G. Sutter, G. L. Smith, and H. Hengel. 2009. Gamma interferon-induced regulatory factor 1-dependent antiviral response inhibits vaccinia virus replication in mouse but not human fibroblasts. Journal of Virology. 83:3684-3695.
   
   
3. Waibler, Z., M. Anzaghe, T. Frenz, A. Schwantes, C. Pöhlmann, H. Ludwig, M. Palomo-Otero, A. Alcami, G. Sutter, and U. Kalinke. 2009. Vaccinia virus-mediated inhibition of type I interferon responses is a multifactorial process involving the soluble type I interferon receptor B18 and intracellular components. Journal of Virology. 83:1563-1571.
   
   
4. Waibler, Z., M. Anzaghe, H. Ludwig, S. Akira, S. Weiss, G. Sutter, and U. Kalinke. 2007. Modified vaccinia virus Ankara induces Toll-like receptor independent type I interferon responses. Journal of Virology. 81:12102-12110.
   
   
5. Ludwig, H., Y. Suezer, Z. Waibler, U. Kalinke, B. S. Schnierle, and G. Sutter. 2006. The double stranded RNA-binding protein E3 controls translation of viral intermediate RNA marking an essential checkpoint in modified vaccinia virus Ankara infected cells. Journal of General Virology. 87:1145-1155.
   
   
6. Kastenmüller, W., I. Drexler, H. Ludwig, V. Erfle, C. Peschel, H. Bernhard, and G. Sutter. 2006. Infection of human dendritic cells with recombinant vaccinia virus MVA reveals general persistence of viral early transcription but distinct maturation-dependent cytopathogenicity. Virology. 350:276-288.
   
   
7. Blencke, H.-M., I. Reif, F. M. Commichau, C. Detsch, I. Wacker, H. Ludwig, and J. Stülke. 2006. Regulation of citB expression in Bacillus subtilis: integration of multiple metabolic signals in the citrate pool and by the general nitrogen regulatory system. Archives of Microbiology. 185:136-146.
   
   
8. Ishii, K. J., C. Coban, H. Kato, K. Takahashi, Y. Torii, F. Takeshita, H. Ludwig, G. Sutter, K. Suzuki, H. Hemmi, S. Sato, M. Yamamoto, S. Uematsu, T. Kawai, O. Takeuchi, and S. Akira. 2006. A Toll-like receptor-independent antiviral response induced by double-stranded B-form DNA. Nature Immunology. 7:40-48.
   
   
9. Fischer, S. F., H. Ludwig, J. Holzapfel, M. Kvansakul, L. Chen., D. C. S. Huang, G. Sutter, and G. Häcker. 2006. Modified vaccinia virus Ankara protein F1L is a novel BH3-domain binding protein and acts together with the early viral protein E3L to block virus-associated apoptosis. Cell Death & Differentiation. 13:109-118.
   
   
10. Ludwig, H., J. Mages, C. Staib, M. H. Lehmann, R. Lang, and G. Sutter. 2005. Role of viral factor E3L in vaccinia virus MVA infection of human HeLa cells: Regulation of the virus life cycle and identification of differentially expressed host genes. Journal of Virology. 79:2584-2596.
    
    
11. Wacker, I., H. Ludwig, I. Reif, H.-M. Blencke, C. Detsch, and J. Stülke. 2003. The regulatory link between carbon and nitrogen metabolism in Bacillus subtilis: regulation of the gltAB operon by the catabolite control protein CcpA. Microbiology. 149:3001-3009.
    
    
12. Blencke, H.-M., G. Homuth, H. Ludwig, U. Mäder, M. Hecker, and J. Stülke. 2003. Transcriptional profiling of gene expression in response to glucose in Bacillus subtilis: regulation of the central metabolic pathways. Metabolic Engineering. 5:133-149.
    
    
13. Ludwig, H., H.-M. Blencke, M. Schmalisch, C. Detsch, M. Merzbacher, and J. Stülke. 2003. Positive regulation of gene expression by the catabolite control protein CcpA in Bacillus subtilis. In: Regulatory Networks in Prokaryotes. Dürre, P., and Friedrich, B. (eds.) Norfolk: Horizon Scientific Press. Chapter 27:181-186.
    
    
14. Meinken, C., H.-M. Blencke, H. Ludwig, and J. Stülke. 2003. Expression of the glycolytic gapA operon in Bacillus subtilis: mRNA processing contributes to differential syntheses of proteins encoded by the operon. Microbiology. 149:751-761.
    
    
15. Ludwig, H., C. Meinken, A. Matin, and J. Stülke. 2002. Insufficient expression of the ilv-leu operon encoding enzymes of branched-chain amino acids biosynthesis limits growth of a Bacillus subtilis ccpA mutant. Journal of Bacteriology. 184:5174-5178.
    
    
16. Ludwig, H., N. Rebhan, H.-M. Blencke, M. Merzbacher, and J. Stülke. 2002. Control of the glycolytic gapA operon by the catabolite control protein A in Bacillus subtilis: a novel mechanism of CcpA-mediated regulation. Molecular Microbiology. 45:543-553.
    
    
17. Ludwig, H., G. Homuth, M. Schmalisch, F. M. Dyka, M. Hecker, and J. Stülke. 2001. Transcription of glycolytic genes and operons in Bacillus subtilis: evidence for the presence of multiple levels of control of the gapA operon. Molecular Microbiology. 41:409-422.
    
    
18. Ludwig, H. and J. Stülke. 2001. The Bacillus subtilis catabolite control protein CcpA exerts all its regulatory functions by DNA-binding. FEMS Microbiology Letters. 203:125-129.
    
    
19. Krüger, E., D. Zühlke, E. Witt, H. Ludwig, and M. Hecker. 2001. Clp-mediated proteolysis in Gram-positive bacteria is autoregulated by the stability of a repressor. The EMBO Journal. 20:852-863.